Evidence map›Paper›PMID 40672373›Full record

ArticleFrontiers in pharmacology2025

Acute pharmacological effects of α-PVP in humans: a naturalistic observational study.

Georgina De la Rosa, Esther Papaseit, Olga Hladun, Lourdes Poyatos, Dolly Andrea Caicedo, Martha Catalina Argote, Soraya Martín, Mireia Ventura, Nunzia La Maida, Annagiulia Di Trana and 4 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Alfa-PVP: Why Does Finland Stick Out?Nordisk alkohol- & narkotikatidskrift : NAT · 2026
    Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Georgina De la RosaClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Esther PapaseitClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Olga HladunClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Lourdes PoyatosClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Dolly Andrea CaicedoClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Martha Catalina ArgoteClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Soraya MartínClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Mireia VenturaEnergy Control, Associació Benestar i Desenvolupament, Barcelona, Spain.
Nunzia La MaidaNational Center on Addiction and Doping, National Institute of Health, Rome, Italy.
Annagiulia Di TranaNational Center on Addiction and Doping, National Institute of Health, Rome, Italy.
Silvia GrazianoNational Center on Addiction and Doping, National Institute of Health, Rome, Italy.
Simona Pichini *National Center on Addiction and Doping, National Institute of Health, Rome, Italy.
Magí Farré *Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Clara Pérez-Mañá *Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alpha-pyrrolidinopentiophenone (α-PVP) is a commonly consumed analogue of pyrovalerone, a synthetic cathinone with psychostimulant properties similar to those of 3,4-Methylenedioxypyrovalerone (MDPV) and cocaine. Since the pharmacology of α-PVP remains scarcely studied, we aimed to evaluate the acute pharmacological effects and its abuse potential in humans after intranasal administration. Methods: We carried out a non-controlled observational study in a naturalistic environment in nine participants (3 women and six men) with a previous history of psychostimulant use. Participants self-administered a single intranasal dose of 10mg or 20mg of α-PVP. The outcomes included physiological effects (systolic and diastolic blood pressure, heart rate, and temperature) and subjective effects (Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire_VESSPA-SSE, the short form of the Addiction Research Center Inventory questionnaire_ARCI and visual analog scales_VASs) and were measured at different time points (0, 20 and 40 minutes and 1, 1.5, 2, 2.5, 3, 4 and 5 hours). Results: An acute increase in blood pressure and heart rate was observed that peaked 40 minutes after administration. Subjective effects also showed a rapid onset and disappeared 3 to 5 hours after administration. Discussion: α-PVP showed psychostimulant properties similar to those displayed by cocaine and empathogenic effects commonly associated with MDMA and other cathinones (eg. methylone) consumption.

Indexed as

alpha-pyrrolidinopentiophenone (α-PVP)cathinonesnew psychoactive substancespharmacologypsychostimulants

Identifiers

PMID40672373
PMCPMC12263604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.